Translational control of gene expression has recently been recognized as an important mechanism controlling cell proliferation and oncogenesis, and it mainly occurs in the initiation step of protein synthesis that involves multiple eukaryotic initiation factors (eIFs). Many eIFs have been found to have aberrant expression in human tumors and the aberrant expression may contribute to oncogenesis. However, how these previously considered house-keeping proteins are potentially oncogenic remains elusive. In this study, we investigated the expression of eIF3i in human colon cancers, tested its contribution to colon oncogenesis and determined the mechanism of eIF3i action in colon oncogenesis. We found that eIF3i expression was upregulated in both human colon adenocarcinoma and adenoma polyps as well as in model inducible colon tumorigenic cell lines. Overexpression of ectopic eIF3i in intestinal epithelial cells causes oncogenesis by directly upregulating the synthesis of cyclooxygenase-2 (COX-2) protein and activates the b-catenin/T-cell factor 4 signaling pathway that mediates the oncogenic function of eIF3i. Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translationally upregulating COX-2 and activating the b-catenin signaling pathway. These findings imply that proto-oncogenic eIFs likely exert their tumorigenic function by regulating/altering the synthesis level of downstream tumor suppressor or oncogenes.
INTRODUCTION
Translational control is one of the primary regulations of gene expression and it mainly takes place in the initiation step of protein synthesis, which in eukaryotes involves more than 10 eukaryotic initiation factor (eIF) complexes. 1 Many of these eIFs, in particular eIF4E, have been shown to regulate protein synthesis, participate in signal transduction and associate with human cancers. 2 eIF3, the largest eIF complex consisting of 13 putative subunits (eIF3a-eIF3m) is an important factor in maintaining free 40S ribosomes and in forming the 43S pre initiation complex. [3] [4] [5] Several eIF3 subunits have been found to have altered expression in human cancers and possibly associate with the disease, whereas some of them have been shown to have oncogenic properties. However, how an eIF3 subunit contributes to oncogenesis remains elusive.
In this study, we took eIF3i as a model protein and investigated its mechanism of action in colon oncogenesis. In both human colon adenocarcinoma and adenoma polyps, eIF3i expression is upregulated. It is also upregulated in inducible colon tumorigenic cell lines. Overexpression of ectopic eIF3i causes colon oncogenesis as determined in vitro and in a xenograft animal model. Further analyses revealed that eIF3i overexpression directly upregulates the synthesis of functionally active cyclooxygenase-2 (COX-2), which, in turn, activates the b-catenin/T-cell factor-4 (TCF4) signaling pathway that mediates the oncogenic function of eIF3i. Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by upregulating COX-2 synthesis and activating the b-catenin signaling pathway.
RESULTS

Association of eIF3i expression with colon cancers
To determine the expression status of eIF3i in colon cancer, we collected and performed western blot analysis of 22 matched pairs of fresh frozen human colon normal and cancer tissues. As shown in Figure 1a , 16 of the 22 cancer tissues (B73%) have increased eIF3i level than their respective matched normal tissues. This increase is statistically significant (Figure 1b) . Figure 1c shows immunofluorescence staining of a representative pair of human colon normal and cancer tissues, confirming the elevated eIF3i expression in cancer tissues. eIF3i expression also appears to be increased in benign adenoma polyps (Supplementary Figure S1) . We also tested the expression of the known eIF3i-binding proteins, eIF3b and eIF3g, 6 in these tissues. Although eIF3b expression remained the same between normal and cancer tissues, the expression of eIF3g is decreased in most cancer tissues (data not shown). Thus, the eIF3i-binding proteins, eIF3b and eIF3g, do not increase in concert with eIF3i in human colon cancers.
We next examined the expression pattern of eIF3i in two rat intestinal epithelial cell lines, IEC-iK Ras and RIE-iH Ras, which can be transformed by inducing the expression of the mutant Ras using isopropylthio-b-galactoside. As expected, both cell lines have significant increases in foci formation (Figure 2a ), proliferation ( Figure 2b ) and colony formation (Figure 2c ) following the induction of Ras expression (Figure 2d ). Interestingly, eIF3i expression is also increased in these cells following Ras induction (Figure 2d ), suggesting that eIF3i expression also associates with inducible cell transformations and it may be a downstream target gene of Ras.
We further examined the association of eIF3i expression with colon cancer using CaCo-2 cell line that can differentiate into the intestine-like cells and lose cancer phenotype upon confluency as indicated by the expression of brush-border enzymes such as alkaline phosphatase (AP), a differentiation marker of the colon epithelial cells. [7] [8] [9] [10] We first determined eIF3i expression in response to confluency using western blot. Figures 3a and b show that eIF3i expression decreases when cells reach confluency and begin to differentiate as indicated by the increased AP activity (Figure 3c ), Together, these findings suggest that eIF3i expression positively associates with the colon cancer phenotype.
Contribution of eIF3i overexpression to colon oncogenesis The finding that eIF3i expression is upregulated in colon benign polyps suggests that eIF3i upregulation may occur before Figure 2 . Association of eIF3i upregulation with inducible transformation of rat intestinal epithelial RIE-iH Ras and IEC-iK Ras cells. RIE-iH Ras and IEC-iK Ras cells were treated with or without isopropylthio-b-galactoside (IPTG) for 72 h followed by the analysis of foci formation (a), proliferation (b), anchorage-independent growth (c) and eIF3i and Ras expression (d). Actin was used as a loading control for western blot. (n ¼ 3; *Po0.05; **Po0.01). CaCo-2 cells were harvested at different times followed by western blot analysis of eIF3i expression (a), quantitation of eIF3i level in a using Image J software (http://rsbweb.nih.gov/ij/) (b), and the analysis of AP activity (c). a shows a representative experiment and b, c show the summary of three independent experiments. GAPDH was used as a loading control and for normalization during quantification. (d, e). Effect of eIF3i expression on CaCo-2 cell differentiation. Pre-(Pre-C) and post confluent (Post-C) cells were transfected with eIF3i complementary DNA (cDNA) (eIF3i) and siRNA (Si) to enforce and reduce eIF3i expression, respectively, followed by the analysis of eIF3i level (d) and alkaline phosphatase activity (e). Vector (Vec)-and scrambled siRNA (Scr)-transfected cells were used as controls. Untransfected pre-and post-confluent cells were also analyzed as controls. (n ¼ 3; *Po0.05; **Po0.01). eIF3i in oncogenesis and b-catenin signaling J Qi et al oncogenesis. To determine whether eIF3i overexpression possibly contributes to colon oncogenesis, we first examined whether reducing eIF3i expression in CaCo-2 cells would reduce oncogenic property and contributes to confluency-induced differentiation. For this purpose, CaCo-2 cells were allowed to grow to confluency and then transiently transfected with eIF3i for ectopic overexpression ( Figure 3d ) followed by the analysis of AP. Figures 3d and e show that ectopic overexpression of eIF3i suppressed confluency-induced differentiation as indicated by the reduced AP activity, suggesting that eIF3i overexpression inhibits confluencyinduced-loss of cancer phenotype of CaCo-2 cells. Conversely, eIF3i knockdown in pre confluent cells effectively induced differentiation as indicated by the increased AP activity (Figures  3d and e) , suggesting that eIF3i knockdown can potentially reverse the cancer phenotype of CaCo-2 cells.
To further determine the role of eIF3i in colon oncogenesis, we used the normal rat intestinal epithelial cells (IEC) and determined whether eIF3i overexpression could transform these cells. This cell was chosen because colon cancer arises from IEC, and the rat IEC cell is well characterized and widely used for oncogenic research. Two stable clones with eIF3i overexpression (eIF3i-1 and eIF3i-2) along with a vector-transfected control clone (Vec) were established ( Figure 4a ) and tested for their proliferation rate, colony formation efficiency and anchorage-independent growth. Figure 4b shows that both eIF3i-1 and eIF3i-2 stable clones proliferate much faster than the Vec control cells. Both eIF3i-1 and eIF3i-2 clones also have significant increases in colony formation efficiency ( Figure 4c ) and in anchorage-independent growth in both colony size and numbers (Figure 4d ). Together, these observations suggest that ectopic eIF3i overexpression can effectively transform normal IEC cells.
We next examined whether these two stable IEC clones could form xenograft tumors. Equal numbers of eIF3i-1, eIF3i-2 and control Vec cells were injected subcutaneously into different groups of nonobese diabetic/severe combined immunodeficient mice and followed by observation for 9 weeks. As shown in Figure 4e , tumors were formed and palpable 2 weeks after implantation and grow exponentially from eIF3i-1 and eIF3i-2 clones in all animals (three mice for each clone). The average size of these tumors reached about 250 mm 3 at 9 weeks after implantation. The average weight of these tumors at 9 weeks is 0.16 ± 0.09 g. Hematoxylin & eosin staining of paraffin-embedded sections of xenograft tumors showed typical adenocarcinoma characteristics (Figure 4f ). Xenograft tumors continue to express high level of eIF3i (Figure 4g ). However, no tumor was formed from any of the three animals that were injected with the Vec control cells. Taken together, we conclude that eIF3i overexpression contributes to colon oncogenesis. eIF3i activates b-catenin/TCF4 signaling The finding that eIF3i overexpression increases cell proliferation indicates that eIF3i may affect cell cycle progression. To test this possibility, we analyzed cell cycle distributions and found that eIF3i-1 and eIF3i-2 clones have increased S (B47%) and decreased G0/G1 (B41%) phase populations compared with the Vec control cells that have 35% S and 51% G0/G1 phase cells (Figure 5a ). This observation is consistent with the increased proliferation of eIF3i-1 and eIF3i-2 stable cells (Figure 4b ). To verify that the increase in S phase population was due to eIF3i overexpression, we knocked down eIF3i level in both eIF3i-1 and eIF3i-2 clones using small interfering RNA (siRNA) (Supplementary Figure S2A ) and tested its effect on S phase population. Supplementary Figure S2B shows that the S phase population was effectively decreased in both eIF3i-1 and eIF3i-2 clones following eIF3i knockdown. Thus, eIF3i may have an important role in regulating cell proliferation by regulating S phase entry.
As cyclin D1 is an important cyclin for S phase entry, we then determined cyclin D1 expression using western blot analysis and found that it was drastically increased in both eIF3i-1 and eIF3i-2 clones (Figure 5b ). Real-time reverse transcription-PCR analyses showed that the mRNA level of cyclin D1 was also increased in both eIF3i-1 and eIF3i-2 stable clones ( Figure 5c ). However, the expression of cyclin E was not changed. Therefore, cyclin D1, not cyclin E, is likely a downstream mediator of eIF3i in cell proliferation and cell cycle regulation.
To investigate how eIF3i regulates cyclin D1 expression, we hypothesized that b-catenin, which promotes cyclin D1 transcription and also a known proto-oncogene and major mediator of adenomatous polyposis coli in colon oncogenesis, 11 might be activated by eIF3i. To test this hypothesis, we first determined whether another well-known b-catenin downstream target gene, c-Myc, is upregulated similarly as cyclin D1 by eIF3i. As shown in Figures 5b and c Myc expression is increased in both eIF3i stable clones. Next, we used luciferase reporter assay, where the luciferase gene is driven by a promoter containing a b-catenin/ TCF4 element, to monitor the b-catenin activity. As shown in Figure 5d , eIF3i overexpression increases b-catenin activity by 1.7-to 2.8-folds. Immunofluorescence staining also shows the increase Figure S3) . To further determine whether the increase in b-catenin activity in eIF3i-1 and eIF3i-2 clones was due to eIF3i overexpression, we transiently knocked down eIF3i expression using siRNA followed by testing the b-catenin activity using luciferase reporter assay. Figure 5e shows the knockdown of eIF3i in these cells, and Figure 5f shows that the b-catenin activity is effectively reduced in eIF3i knockdown cells compared with the scrambled siRNA-transfected control cells. To verify these findings and to eliminate cell line specificity, we investigated the effect of eIF3i on b-catenin activity in RIE cells and CaCo-2 cells. As shown in Supplementary Figure S4A , eIF3i overexpression significantly increases b-catenin activity in RIE cells. Interestingly, following confluency and differentiation of CaCo-2 cells, the b-catenin activity is dramatically decreased (Supplementary Figure S4B) , which coincides with the reduced eIF3i expression following confluency (see Figure 3) . Furthermore, transient eIF3i overexpression in the post confluent CaCo-2 cells increased, whereas transient eIF3i knockdown in pre confluent CaCo-2 cells decreased the b-catenin activity (Supplementary Figure S4B ). These observations strongly support the possible role of eIF3i in regulating b-catenin activity.
Cyclooxygenase-2 is the direct effector of eIF3i in b-catenin activation Prostaglandin E2 (PGE 2 ), a product of COX-2, promotes colon cancer cell growth by activating and stabilizing b-catenin. 12 To determine whether eIF3i possibly increases COX-2 expression and, thus, PGE2 production, which in turn activates b-catenin, we first performed a western blot analysis of COX-2 in the stable IEC clones. As shown in Figure 6a , both eIF3i-1 and eIF3i-2 clones have much higher level of COX-2 than the control cells. Also, transient eIF3i overexpression in post confluent or knockdown in pre confluent CaCo-2 cells increased and decreased the COX-2 level, respectively (Supplementary Figure S5) . Furthermore, the increased COX-2 level is accompanied with an increased PGE 2 production in eIF3i-1 and eIF3i-2 clones (Figure 6b ). Thus, eIF3i overexpression likely increases the level of the functionally active COX-2.
To determine whether COX-2 is responsible for eIF3i-mediated upregulation of b-catenin activity, we next knocked down COX-2 expression in eIF3i-1 and eIF3i-2 clones and monitored the change in the b-catenin activity using reporter assay. Figures 6c and d show that reducing COX-2 expression using siRNA significantly reduced b-catenin activity. We also found that COX-2 overexpression in RIE cells dramatically increased b-catenin activity (Supplementary Figure S6A) Finally, to determine whether COX-2 and b-catenin mediates the oncogenic function of eIF3i, we performed a colony formation assay of eIF3i-1 and eIF3i-2 clones following transient knockdown of COX-2 or b-catenin ( Figure 6c ). As shown in Figure 6e , the colony formation potential of both eIF3i-1 and eIF3i-2 clones were reduced about 50% by COX-2 or b-catenin knockdown. Likely, COX-2 and b-catenin partly mediate the oncogenic function of eIF3i.
Translational regulation of COX-2 by eIF3i
In order to elucidate the potential mechanisms of eIF3i regulation of COX-2, we determined the potential effect of eIF3i on COX-2 protein synthesis with consideration of the potential role of eIF3i in translational control. Figure 7a shows that the synthesis of endogenous COX-2 in the eIF3i-overexpressing IEC cells is much faster than that in the Vec control cells as determined using pulse labeling in combination with immunoprecipitation and autoradiography. To determine whether eIF3i regulation of COX-2 synthesis is a direct effect not indirectly by regulating the expression of another gene, we used the in vitro transcription/translation system to program translation of COX-2 in the absence or presence of purified eIF3i. In this system, only COX-2 is newly expressed by programing its translation with purified COX-2 complementary RNA (cRNA). Supplementation of eIF3i will not affect the level of any other proteins in this system. Figures 7b and c show that the supplementation of purified eIF3i significantly upregulates the synthesis of COX-2 in a dose-dependent manner. However, the supplementation of purified 14-3-3s, an irrelevant protein of similar size as eIF3i as a control, did not affect the synthesis of COX-2. To eliminate the possibility that eIF3i potentially stimulates the translation of all transcripts in the in vitro system, we also tested the translation of 14-3-3s cRNA. As shown in Figure 7d , the addition of purified eIF3i to the in vitro system increased the translation of COX-2 but not that of 14-3-3s cRNAs.
To further demonstrate the direct effect of eIF3i on COX-2 synthesis, we performed a pull-down assay of purified eIF3i using biotin-labeled COX-2 cRNA. As shown in Figure 8a , dramatically eIF3i in oncogenesis and b-catenin signaling J Qi et al more purified eIF3i is pulled down by the biotin-labeled COX-2 cRNA probe than the unlabeled control COX-2 cRNA probe. The binding of eIF3i to the biotin-labeled COX-2 cRNA probe could be completely inhibited by the unlabeled probe (Figure 8b) , suggesting that the binding is specific. However, the control biotin-labeled 14-3-3s cRNA probe did not pull down any purified eIF3i, indicating that it cannot bind to eIF3i (Figure 8b ) and that eIF3i regulation of COX-2 synthesis may be specific. Similarly, using RNA-electrophoretic mobility shift assay, we found that purified eIF3i could bind directly to [ 32 P]-labeled COX-2 but not 14-3-3s cRNA probes and that the unlabeled COX-2 competitor cRNA probe could completely block the binding between eIF3i and the [ 32 P]-labeled COX-2 cRNA probe (Figure 8c ). Thus, we conclude that eIF3i likely upregulates the COX-2 synthesis by directly binding to COX-2 mRNA.
We also tested whether eIF3i upregulation in colon cancer tissues correlates with COX-2 expression. Supplementary Figure S8 shows that the COX-2 level is increased in 11 of 12 (B92%) cancer colon tissues with increased eIF3i expression. COX-2 remains unchanged in two cancer tissues that do not have increased eIF3i. Together with above observations, these findings suggest that eIF3i may upregulate COX-2 expression in human colon cancer tissues.
DISCUSSION
The findings that eIF3i is overexpressed in human colon cancer tissues and drives colon oncogenesis along with previous findings on eIF3i overexpression in the head and neck cancer, 13 breast cancer, 14 hepatocellular carcinoma, 15 neuroblastoma and melanoma, 16 suggest that eIF3i overexpression may be a oncogenic factor. In supporting this conclusion, it has been shown previously that overexpression of ectopic eIF3i causes the transformation of mouse fibroblast NIH3T3 and human endothelial ECV304 cells. 17 Further studies using in vivo animal models on other cancers such as breast cancer are needed to demonstrate the oncogenic function of eIF3i for these cancers.
Although it was previously thought that the eIF3 complex behaves as a house-keeping initiation factor, accumulating evidences suggest that subunits of this complex may have additional functions in regulating protein synthesis and cell proliferation. 3, 5 One such good example is eIF3a, which has been extensively demonstrated to regulate protein synthesis and cell proliferation. [17] [18] [19] [20] [21] It has been shown that eIF3a upregulation causes the transformation of fibroblast 17 and its downregulation reverses malignant phenotype of cancer cells. 18 Interestingly, eIF3a upregulation does not upregulate the synthesis of all proteins. In fact, the synthesis of some proteins including potential tumor suppressors such as p27, XPA and RPA are inhibited by eIF3a overexpression. 20, 22, 23 Similarly, eIF3i may also have an important role in regulating protein synthesis. The finding in this study that eIF3i (d) Effect of eIF3i on in vitro translation of 14-3-3s cRNA. 14-3-3-s and COX-2 cRNAs were use to program cell-free translation in the absence or presence of purified eIF3i and the newly synthesized 14-3-3s and COX-2 were separated by SDS-PAGE and detected using autoradiograph as described for b.
eIF3i in oncogenesis and b-catenin signaling J Qi et al overexpression upregulates the synthesis of COX-2 supports this argument. Recently, we found that, similar to eIF3a, eIF3i upregulation inhibits the synthesis of p27 (unpublished observation), further supporting the regulatory role of eIF3i in protein synthesis. Although eIF3i does not have any known RNA-binding motif, the fact that purified eIF3i can directly bind to COX-2 but not to 14-3-3s cRNAs argues that eIF3i alone may be able to bind and stimulate COX-2 synthesis. eIF3a can also bind to mRNAs without any known RNA-binding motif. 24, 25 It is, thus, tempting to speculate that these proteins may have an unknown RNA-binding sequence. The possibility that by forming inactive subcomplexes with other eIF3 subunits, 4, [26] [27] [28] eIF3i overexpression suppresses general translation, which leads to the upregulation of translation of specific mRNAs such as COX-2 as suggested previously for eIF3a, 17 cannot be ruled out. However, increased cellular proliferation due to eIF3i overexpression is inconsistent with the suppression of general protein synthesis. The finding that the eIF3i-binding partners do not increase in concert with eIF3i in cancer tissues also argues against this possibility. COX-2 mRNA has been shown to contain an AU-rich element in its 3 0 -untranslated region that inhibits COX-2 mRNA translation 29, 30 and accelerate COX-2 mRNA degradation. However, we found that the increased eIF3i expression does not appear to affect the degradation of COX-2 mRNA in IEC cells (unpublished observation) and, thus, we believe that eIF3i does not affect COX-2 mRNA stability. Nevertheless, it will be of interest to determine whether eIF3i possibly binds to the inhibitory AU-rich element in the 3 0 -untranslated region of COX-2 mRNA to potentially relieve the inhibitory effect of AU-rich element on the translation of COX-2 mRNAs. We are currently testing this possibility.
COX-2 and its product PGE2 have been shown to have an important role in oncogenesis and disease progression possibly by activating b-catenin in the Wnt/b-catenin signaling pathway. [31] [32] [33] PGE2 has been shown to promote b-catenin stabilization and activation in colon cancer cell lines by displacing glycogen synthase kinase-3b from the b-catenin complex and, thus, preventing its phosphorylation and degradation. 12, 34 Indeed, eIF3i overexpression upregulates COX-2 synthesis, increases the production of PGE2 and increases b-catenin activity. Knocking down COX-2 or b-catenin could partially reverse malignant phenotype induced by eIF3i overexpression. Hence, it is not surprising to find that eIF3i has oncogenic functions.
COX-2 and its product PGE2 may be one of many eIF3i downstream targets that mediate the oncogenic function of eIF3i. This possibility is consistent with the finding that knocking down of COX-2 expression in the eIF3i-overexpressing cells only partially reversed the eIF3i-overexpression-induced malignant phenotype ( Figure 6 ) and that the expression of a tumor suppressor gene p27 is inhibited by eIF3i overexpression (unpublished observation). Currently, what other genes possibly mediate the oncogenic function of eIF3i is unknown. However, it has been found that the C-terminus of eIF3i interacts with Akt, which is required for eIF3i-mediated Akt activation 35 and that mammalian target of rapamycin inhibition reduces eIF3i phosphorylation and eIF3i oncogenic activity. 36 As Akt is known to mediate the effect of K-ras on COX-2 expression, 37 eIF3i may participate in the intricate signaling network involving Akt, K-ras and COX-2 in colon oncogenesis.
Equally important but unknown issues regarding eIF3i is its upstream regulator in colon oncogenesis. Our findings using the Ras inducible cell lines suggest that eIF3i may be under the control of Ras. Considering that 30-50% of colon cancers have K-Ras mutation, the finding that eIF3i may be under K-Ras control and contribute to colon oncogenesis by regulating the translation of its downstream target genes is important and may have significant impact on future studies of colon cancer. However, it is noteworthy that all colon cancer tissues examined in this study appear to have increased eIF3i expression. This is consistent with genomic data (www.oncomine.org), where increased eIF3i expression was observed in adenoma and adenocarcinoma compared with normal tissues. With the average rate of K-ras mutation in colon cancers as 30-50%, it is not clear whether K-ras regulates eIF3i expression in human tissues and there may be other mechanisms that upregulate eIF3i expression.
One of the other potential regulators of eIF3i expression is signaling from cell-cell contact. It appears that eIF3i expression decreases as CaCo-2 cells reaches confluency. Further studies are needed to investigate what signaling pathways are possibly involved in suppressing eIF3i expression in response to confluency. Nevertheless, eIF3i reduction in response to confluency may be responsible for the confluency-induced CaCo-2 cell differentiation. This is consistent with our previous finding that eIF3a may have a role in differentiation and that the decreased eIF3a expression could be a prerequisite of IEC differentiation. 21 In summary, we showed that eIF3i is a proto-oncogene, functioning by upregulating the COX-2 synthesis and PGE2 production, which in turn activates b-catenin (Figure 8d ). The regulation of COX-2 synthesis appears to be via direct binding of eIF3i to its mRNA. These findings suggest that eIF3i unlikely participates in protein synthesis only as a subunit of the housekeeping eIF3 complex and it may have additional non-canonic functions and have an important regulatory role in protein synthesis, cell proliferation and oncogenesis.
MATERIALS AND METHODS Materials
Antibodies against eIF3i, cyclin D1, COX-2 and siRNAs targeting human TCF4, b-catenin and COX-2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Cyclin E, b-catenin and TCF4 were from Cell Signaling Technology (Beverly, MA, USA). TOP-FLASH and FOP-FLASH reporter plasmids and anti-pan-Ras antibody were from EMD Millipore (Billerica, MA, USA). Anti-GAPDH and b-actin antibodies were from Abcam Inc. (Cambridge, MA, USA). Anti-His-Tag antibody, horseradish peroxidaseand fluorescein isothiocyanate-labeled secondary antibodies were from Sigma-Aldrich (St Louis, MO, USA). siRNAs targeting rat b-catenin and COX-2 and human eIF3i were from Dharmacon (Lafayette, CO, USA). RNeasy Mini Kit, SYBR Green qPCR Master Mixes, [ 35 S]methionine, and enhanced chemiluminenscence (ECL) were from Qiagen (Valencia, CA, USA), Applied Biosystems (Foster City, CA, USA), Perkin Elmer (Boston, MA, USA) and GE Healthcare (Pittsburgh, PA, USA), respectively. Culture media, reagents and pCMV-b-gal were from Invitrogen (Grand Island, NY, USA). Luciferase Reporter Assay Kit and Streptavidin-magnetic beads were from Promega (Madison, WI, USA). Bradford reagents and iScript complementary DNA (cDNA) Synthesis Kit were from Bio-Rad Laboratories (Berkeley, CA, USA). All other reagents of molecular biology grade were from Sigma or Fisher Scientific (Chicago, IL, USA).
Human tissues
Frozen and paraffin-embedded surgical specimens of matched human colon cancer and adjacent normal tissues were from IUSCC (Indiana University Simon Cancer Center) Tissue Procurement and Distribution Core at Indiana University School of Medicine, Indianapolis, IN, USA. These tissues were verified by certified pathologist at the IUSCC.
Construct engineering
The mammalian eIF3i expression construct was engineered by releasing the eIF3i cDNA from pOTB7/eIF3i (Open Biosystems, Huntsville, AL, USA) and cloning it into pCbA to generate pCbA/eIF3i. To generate the plasmid for the production of recombinant protein, eIF3i cDNA in pOTB7/eIF3i was amplified by PCR using primers 5 0 -GGAATTGATGAAGCCGATCCTACTG CAGGGC-3 0 (forward) and 5 0 -CCTCGAGTTAAGCCTCAAACTCAAATTCGAA GTA-3 0 (reverse). The PCR product was then cloned into pET28a to generate pET28a/eIF3i. The COX-2 expression plasmid was engineered by releasing human COX-2 cDNA from COX-2/SPORT6 plasmid (Open Biosystems) and cloning it into pCbA, resulting in pCbA/COX-2. All plasmids were confirmed by DNA sequencing.
Cell lines and transfection IEC-6, IEC-iK Ras 30 and RIE-iH Ras 37 cell lines that harbor inducible K-Ras
Val12
and Ha-Ras Val12 gene, respectively, were gifts from Dr Hongmiao Sheng (Indiana University School of Medicine). CaCo-2 was obtained from ATCC (Manassas, VA, USA). RIE-iH Ras and IEC-iK Ras cells were cultured in selective Dulbecco's modified Eagle Medium medium containing 400 mg/ ml G418 and 150 mg/ml hygromycin B. For confluency studies, CaCo-2 cells were seeded into 60 mm dishes at 1 Â 10 6 cell per dish and cultured for various time with medium changed every 2 days.
Transient transfections were performed using Lipofectamine Plus reagent or Lipofectin 2000 (Invitrogen) as we previously described. [18] [19] [20] Cells were harvested for analysis at 48 h following transfection. For cotransfections, the secondary construct or siRNAs were introduced into cells at 24 h following the first transfection. To establish stable transfectants, IEC cells were transfected with pCbA/eIF3i construct or pCbA vector. Positive clones were selected using G418 and identified using western blot.
RNA purification and real-time reverse transcription-PCR RNA purification and real-time reverse transcription-PCR was performed as previously described. 38 The primers used were 5 0 -AAGGACTCATGACCA CAGTCCAT-3 0 (forward) and 5 0 -CCATCACGCCACAGTTTCC-3 0 (reverse) for GAPDH and 5 0 -CCGTCCATGCGGAAGATC-3 0 (forward) and 5 0 -GAAGACCT CCTCCTCGCACT-3 0 (reverse) for cyclin D1. The threshold cycle (Ct) of cyclin D1 was determined and normalized against that of the internal control, GAPDH.
AP and luciferase reporter assay AP assay was performed as previously described 21 using a kit from SigmaAldrich. Luciferase reporter assay was performed using a kit from Promega according to manufacturer's instructions. The luciferase activity was normalized by b-galactosidase activity and reported as a ratio of TOP-FLASH/FOP-FLASH as previously described. 39 Determination of COX-2 synthesis and PGE2 production Synthesis of COX-2 was analyzed by pulse labeling using [ 35 S]methionine as previously described. 18, 20 Briefly, cells were incubated in methioninefree medium supplemented with [ 35 S]methionine at 300 mCi/ml for 2 h, followed by the lysis of cells and immunoprecipitation of COX-2. The precipitants were separated by 12% SDS-polyacrylamide gel electrophoresis and the COX-2 was detected using autoradiography. The production of PGE 2 was determined using PGE 2 EIA Kit (Cayman, Ann Arbor, MI, USA) according to manufacturer's instructions.
Colony formation, anchorage-independent growth and xenograft tumor formation assays Colony formation and anchorage-independent growth in soft agar were performed as previously described. 18 Briefly, cells were seeded in six-well plates and cultured for 9 days with media changed every 2 days. For growth in soft agar, a base layer of 0.7% Noble agar (BD Biosynthesis, San Jose, CA, USA) in Dulbecco's modified Eagle Medium in 60-mm dish was generated followed by the addition of top layer containing 1000 cells in Dulbecco's modified Eagle Medium and 0.4% agar. Cells were cultured for 14-21 days. Colonies were stained using 0.005% crystal violet and counted manually.
For xenograft tumor formation, B1 Â 10 7 cells were injected subcutaneously into 7-week-old female nonobese diabetic/severe combined immunodeficient mice (one injection/mouse). Tumor growth was measured by a caliper once a week for a total of 9 weeks. The tumor volume was calculated from two perpendicular diameters using the formula: volume ¼ (length/2) Â (width 2 ). Tumors were removed, measured, fixed in 10% formalin buffer and stained with hematoxylin & eosin using standard histology procedures. This study was approved by Indiana University ICAUC.
RNA/protein pull-down assay Pull-down of proteins using biotinylated RNA was performed as previously described. 25 Briefly, streptavidin-magnetic beads were blocked with 3% bovine serum albumin and then incubated with 1 mg biotinylated or naked cRNA probes for 1 h, followed by incubation with 1 mg purified eIF3i for 1 h. The pull-down materials were then washed extensively and separated by SDS-polyacrylamide gel electrophoresis followed by western blot analysis of eIF3i.
Electrophoretic mobility shift assay Electrophoretic mobility shift assay was performed by mixing 1 mg purified His-tagged eIF3i and 150 000 c.p.m. [ 32 P]-labeled COX-2 or 14-3-3s cRNA transcript in a buffer consisting of 15 mM HEPES (pH 7.9), 50 mM KCl, 10% glycerol, 0.2 mM dithiothreitol, 5 mM MgCl 2 , 200 mg/ml tRNA with or without 1 mg unlabeled COX-2 or 14-3-3s cRNA as cold probe competitors followed by the incubation for 30 min at room temperature. Unbound probes were digested by 100 units RNase T1 for 15 min at 30 1C. The reaction mixtures were then separated by non-denaturing polyacrylamide gel electrophoresis and the detection of eIF3i-bound probe using autoradiography.
